Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AJ Complement inhibitors
L04AJ03 Pegcetacoplan
D11613 Pegcetacoplan (JAN/USAN/INN) <JP/US>
S SENSORY ORGANS
S01 OPHTHALMOLOGICALS
S01X OTHER OPHTHALMOLOGICALS
S01XA Other ophthalmologicals
S01XA31 Pegcetacoplan
D11613 Pegcetacoplan (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Immunological Agents
Immunological Agents, Other
Complement Inhibitors
Pegcetacoplan
D11613 Pegcetacoplan (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D11613 Pegcetacoplan (JAN/USAN/INN)
Target-based classification of drugs [BR:br08310]
Peptidases and inhibitors
Peptidase inhibitors
alpha2M family
C3 (C3b)
D11613 Pegcetacoplan (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11613
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11613
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11613
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11613
